Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study

Key facts

Sponsor

Xinhua Zhang, MD

Principal Investigator

zhang xinhua, PhD

First affiliated hosptial,Sun Yat-sen university

Enrollment

100 target

Eligibility

18 years · All sexes

Timeline

2022 – 2025

Study locations (8)

• Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
• Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
• Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
• The first affiliated hospital,Sun yat-sen university, Guangzhou, Guangdong, China
• Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
• Hainan Cancer Hospital, Haikou, Hannan, China
• Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
• The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

Collaborators

Guangdong Provincial People's Hospital · Nanfang Hospital, Southern Medical University · Sixth Affiliated Hospital, Sun Yat-sen University · Peking University Shenzhen Hospital · Cancer Hospital of Guangxi Medical University · Hainan Cancer Hospital · The First Affiliated Hospital of Nanchang University · Second Affiliated Hospital of Nanchang University · Yunnan Cancer Hospital · Chongqing University Cancer Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Gastrointestinal stromal tumor

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07171203
  Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
  University of California, San Diego
• RECRUITINGNANCT07405125
  Safety of Robotic Surgery for GISTs at Special Anatomic Sites
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGPHASE3NCT07218926
  A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
  GlaxoSmithKline
• RECRUITINGPHASE1NCT06655246
  A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
  Kura Oncology, Inc.
• RECRUITINGNANCT06926374
  Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
  Chinese University of Hong Kong
• RECRUITINGNANCT07411118
  RCT of EFTR Versus STER for GIST Treatment
  Chinese University of Hong Kong
• RECRUITINGPHASE1, PHASE2NCT06630234
  A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
  Deciphera Pharmaceuticals, LLC
• RECRUITINGPHASE3NCT06640361
  A Study of Olverembatinib in SDH-deficient GIST.
  Ascentage Pharma Group Inc.

See all trials for Gastrointestinal stromal tumor →